It is said that the great leaders are the ones who are passionate about the products they’re developing. They don’t stop at failures. They don’t let setback put them down, set them aside, and leave them hardened. One of the leaders today who show such attributes may easily be Dr. Clay Siegall of Seattle Genetic.
The Inspirery article that readers can get from Dr. Clay Siegall’s interview would remind everyone that his leadership is sustainable. He not only has grown Seattle Genetic to an IPO level, but also is continuing to stay relevant in the industry of therapeutic drugs. Right now, Siegall is busy in tapping all the opportunities and gathering all of the networks that could support the therapy drugs that he is developing. According to Siegall, Seattle Genetic right now makes money through its proprietary drugs. This is not that hard to accomplish today because of the fact that the FDA has recently approved Seattle Genetic’s antibody-drug conjugate (ADC), for three indications. This is now a great accomplishment that will stamp the quality of the leadership skills of Dr. Siegall.
The recent challenge of Siegall today is to make sure that the drug makers of his company are getting the sustainable support they need. Fortunately, there are enough revenue sources that can make this support happen. There’s still a lot of risks ahead of them, but the fact that it is Siegall that’s overseeing the entire company, then there’s not that much to worry. There’s also a lot of hope for this mainly because Siegall has already the active skills to succeed in such department. He even contributed to making Seattle Genetic profitable enough after 10 years of hard work since being in IPO.
About Clay Siegall
Dr. Siegall has a Ph.D. in Genetics. He also got a B.S. degree in Zoology from the prestigious University of Maryland. Aside from co-founding Seattle Genetics in 1998, he is also the firm’s CEO, President, and Chairman of the firm’s Board of Directors. The company Dr. Siegall has started is also known for developing the most promising antibody-based cancer therapies known today.